FLT3 and acute myeloid leukemia: However, in the COG AAML1031 study, children with newly diagnosed high allelic ratio FLT3-ITD positive AML were eligible for receiving sorafenib combined therapy, and improved EFS was observed for the 72 children who took sorafenib compared to the 76 children who did not [71].